SUN

PHARMA
Presented By :

Shahilsha - 8210
Mohd Saif Siddiqui -8225
Gaurav Ranpise - 8227
Aditi Bulbule - 8237
 INTRODUCTION
❏ The Indian pharmaceutical industry is the World’s 3rd largest by volume
and 14th largest in terms of value.
❏ India is the largest provider of generic drugs globally.
❏ Indian pharmaceutical sector supplies over 50% of global demand for
various vaccines, 40% of generic demand in the US and 25% of all
medicine in the UK.
❏ The domestic pharmaceutical industry includes a network of 3,000 drug
companies and ~10,500 manufacturing units.
❏ According to the Indian Economic Survey 2021, the domestic market is
expected to grow 3x in the next decade.
❏ In August 2021, the Indian pharmaceutical market increased at 17.7%
annually, up from 13.7% in July 2020.
❏ India’s pharmaceutical sector forms a major component of the country’s
foreign trade, with attractive avenues and opportunities for investors.
 SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Sun pharma is India’s top pharmaceutical company.

It is the world’s fourth largest specialty generic pharmaceutical company.

provides high-quality medicines trusted by customers and patients in over 150 countries.
Sun pharma ranked 9 th in US generic market.
43 manufacturing sites across the world.
Sun pharma’s presence is in more than 100 countries across branded and generic market.
37,000+ global employee base.
Sun pharma has highly diversified revenue base.
29 brands in India’s top 300 pharmaceutical brands.
TRENDS IN PERFORMANCE OVER THE PAST 10
YEARS

● CARE has always been an important part of Sun Pharma's mission to provide high-quality
medications that enhance health and save lives.
● Their worldwide positioning and sustained investments enable them to exhibit a resilient
performance while maintaining true to their objectives as a responsible business, with the
pandemic confirming the relevance of generics in healthcare management.
 FY 21 HIGHLIGHTS

● FY21 was a unique year. It witnessed the full brunt of the COVID-19 pandemic across the global
economy and various sectors.
● Governments globally were forced to resort to stringent lockdowns/restrictions to prevent the
spread of the pandemic, which were gradually relaxed in the second half of FY21.
● Most of our businesses have recorded growth for FY21 despite the challenges related to the
global COVID-19 pandemic.
 TOP PRIORITIES FOR FY 22 ARE

● Business growth
● Safety and well-being of employees including facilitation of COVID vaccination for employees
and their immediate family
● Supply chain continuity and inventory optimization
● Continued focus on cost and operational efficiency
● Increased investments in IT to facilitate business and digital transformation
● Focus on improving return ratios
 SPECIAL HIGHLIGHTS
❏ Sun Pharmaceutical Industries Ltd. is the largest pharma company in India and the fourth largest
specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5
Billion.
❏ From the very beginning, Sun Pharma has focused on the high-margin chronic care therapy
products that have made the company very profitable.
❏ Their R&D is led by a strong team of more than 2000 scientists.
❏ In the US, they are among the top 10 generic pharmaceutical companies and are ranked second
by prescriptions in the generic dermatology market.
❏ Sun Pharma is the largest Indian company in emerging markets with a presence in over 80
markets. Brazil, Mexico, Russia, Romania and South Africa are some of their key emerging
markets.
❏ Their R&D centers have been audited and approved by international regulatory authorities,
including the US FDA and European authorities. The R&D centers at Vadodara, & Gurgaon in
 Contd.

❏ Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list in a study
conducted by BlueBytes.
❏ They manufacture and market a large basket of pharmaceutical formulations covering a broad
spectrum of chronic and acute therapies
❏ Their research strategy and implementation are well supported by a strong intellectual property
team having expertise and experience in chemistry, analytical techniques, dosage forms and global
patent law. Sun files numerous patents every year to protect its intellectual property in markets of
interest and they have more than 1400 patents to their credit.
❏ Sun Pharma also focuses on enhancing supply of multiple therapeutics used in the treatment of
COVID-19 and associated ailments, such as Remedy Sivir, Favipiravir, Itolizumab, Liposomal
Amphotericin B, Hydroxychloroquine, etc.
❏ Every year, they sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology,
anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and
respiratory among others.
❏ Recognized as the Best Innovative Company of the Year 2021 at Indo-American Corporate
 FUTURE ROAD MAP
LEVEL 1 LEVEL 2
● Sustained focus on ● Increase retail connect
key brands programs to ensure
● Maintain leadership better availability of our
in existing markets products for end
through a focus on consumers
innovative solutions ● Invest to build the
and brand extensions specialty R&D pipeline
● Enhance presence in ● Develop complex
high growth markets products for global
markets
LEVEL 3
● Target products specifically
for emerging markets and
India
● Continue to work on
developing APIs of strategic
importance
● Enhance systems,
processes, human
capabilities continuously to
ensure compliance with
global regulatory standards
1
O
O
ph
an ph th
t e th al
rio al m
r a mic
nd d ol
po isor og
st de y

2
er rs
io in
re v
D ye olv
se in
er gm g e
In m en ye
u n fla t. su
an m mm at rf
d et a ol ac
ot m to e,
he ed ry og
rs ic an y
as al n d
w ee au

3
el d to
l a s im
s n lik m
O ic e a un
he cn e
N in e, co
nc
co ich ol di at nd
nd e i ca op it
i ti n d
og tio ic io
on ica y ns de ns
s a t io . rm w i
ffe ns at th
ct in iti
in o s
g nc
4

sk o
in lo
. gy
as
w
CN
H el
pr gh i S la
so
t e o d u ly i nc
ch c nt ol
no ts er og
lo for est y
gy t ed
r
pl eat in
at m e
fo en xp
5

rm t an
s a of di
O nd pa ng
fo in b its
rp r m as pi
In ha ig ed pel
re ter ra on in
la es
te te n in e
d e ab po
t o in d In u se rtfo
ab O -d lio
ov rp
di et
er of
e t ha
n
ca re
IN-LICENCING MERGER AND ACQUISITION

he i nt
ra d n to
py i c
ar atio
r
ea n
s
 BUSINESS FOCUS AREAS

● Maintain market
leadership and high
Prioritize
brand equity in India
sustainable and
profitable growth

Enhance share of Gain critical mass across key

specialty products international markets &
in overall business Focus on improving return
ratio
EMERGING MARKETS
 EMERGING MARKETS

● Marketing and

05 distribution of
In-licensing of
innovator products.
Established
Brands/ portfolio 01 04
● In-licensing of
In-licensing of ready
registrations, under Differentiated Products
registration generic
products 02 03 ● Licensing of
Herbal products,
food supplement
 CONCLUSION

Sun Pharma is the largest pharmaceutical company in the domestic market with
8.17% market share and strong positioning in the high-growth chronic segments. It
offers a complete therapy basket, with products in neuropsychiatry, cardiology,
diabetology, gastroenterology, pain/analgesics, gynaecology, ophthalmology,
urology, dermatology, respiratory, anti-infectives, and other segments.The Indian
pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US$21
Billion. It is expected to grow at 7.5-10.5% CAGR to US$28-32 Billion by 2025.